๐๏ธ Verified NIH Record โข Updated 2026-01-29
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer (NCT04176848)
A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: Canadian Cancer Trials Group
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.
Who can join: Review the eligibility criteria below.
Location: BCCA - Cancer Centre for the Southern Interior โ Kelowna, British Columbia
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (5 Sites)
- BCCA - Cancer Centre for the Southern Interior โ Kelowna, British Columbia
- Juravinski Cancer Centre at Hamilton Health Sciences โ Hamilton, Ontario
- Kingston Health Sciences Centre โ Kingston, Ontario
- Ottawa Hospital Research Institute โ Ottawa, Ontario
- University Health Network โ Toronto, Ontario
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer โ Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer โ Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery โ Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) โ Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer โ Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer โ Duarte, California
Explore by condition: All Breast Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.